The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

Novavax, Inc. (NASDAQ:NVAX ... we expect to complete database lock of a related pediatric clinical trial in the fourth ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price ... which has faced delays due to a clinical hold by the FDA. Although the hold ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax yesterday announced that the US Food ... paves the way for it to begin enrolling participants for a phase 3 trial.

Novavax yesterday announced that the US Food ... paves the way for it to begin enrolling participants for a phase 3 trial.